Skip to main content
PLOS One logoLink to PLOS One
. 2023 Nov 27;18(11):e0294810. doi: 10.1371/journal.pone.0294810

Prevalence and the association between clinical factors and Diabetes-Related Distress (DRD) with poor glycemic control in patients with type 2 diabetes: A Northern Thai cross-sectional study

Achiraya Ruangchaisiwawet 1, Narumit Bankhum 2, Krittai Tanasombatkul 1,3, Phichayut Phinyo 1,3,4, Nalinee Yingchankul 1,*
Editor: Shairyzah Ahmad Hisham5
PMCID: PMC10681199  PMID: 38011152

Abstract

Background

Glycemic control is important to prevent diabetic complications. However, evidence linking factors such as diabetes-related distress (DRD) to poor glycemic outcomes is lacking in Thailand. Therefore, this study aimed to investigate the prevalence and associated factors of poor glycemic control type 2 diabetes.

Methods

A cross-sectional study was conducted on 127 type 2 diabetic patients between December 2021 and March 2022 at Maharaj Nakorn Chiang Mai Hospital, Thailand. Data collection included demographic data, clinical data (duration of being type 2 diabetes, diabetic treatment modalities, weight, height, blood pressure, FBS, and HbA1c), behavioral data (self-care behavior, physical activity, dietary assessment, smoking, alcohol consumption, and sleep quality), and psycho-social data (depression and DRD). Poor glycemic control was defined as not achieving the target HbA1c based on the 2021 American Diabetes Association (ADA) Guideline. Multivariable logistic regression was used to explore the associations between potential factors including DRD, and poor glycemic control.

Results

The prevalence of poor glycemic control in patients with type 2 diabetes was 29.1%. Our analysis revealed that age under 65 years old (OR 6.40, 95% CI 2.07–19.77, p = 0.001), obesity (BMI ≥ 25 kg/m2) (OR 2.96, 95% CI 1.05–8.39, p = 0.041), and DRD (OR 14.20, 95% CI 3.76–53.64, p<0.001) were significantly associated with poor glycemic control. Three dimensions of DRD were associated with poor glycemic control, including emotional distress (OR 4.23, 95% CI 1.51–11.85, p = 0.006), regimen-related distress (OR 6.00, 95% CI 1.88–19.18, p = 0.003), and interpersonal distress (OR 5.25, 95% CI 1.39–20.02, p = 0.015).

Conclusion and recommendation

Age, obesity, and DRD are associated with poor glycemic control. A holistic approach that includes addressing DRD is crucial for improving glycemic outcomes in patients with type 2 diabetes. Further studies in broader populations using a cohort design are recommended.

Introduction

Type 2 diabetes mellitus (DM) is a major global health concern with a high prevalence of 462 million cases in 2017 [1], and is expected to rise to 643 million by 2030 [2]. Uncontrolled diabetes can cause many serious complications including retinopathy, nephropathy, neuropathy, and cardiovascular diseases [3], which impact the quality of life, increasing mortality and raising healthcare expenditures [4]. Effective glycemic control is important to prevent diabetic complications. To ensure this, guidelines have been continuously updated to focus on maintaining optimal glycemic levels. However, poor glycemic control remains widespread, i.e., the prevalence of uncontrolled diabetes was 47.3% in Brazil [5], 50.2% in Japan [6], and 76.9% in Saudi Arabia [7]. Thailand ranks fifth in the number of DM cases among Western Pacific countries [2], with 64.4% of DM cases being poorly controlled [8]. In Northern Thailand, the prevalence of poor glycemic control among DM cases was 54.8% [9].

Achieving a glycemic goal is difficult due to numerous factors, which can be divided into demographic factors, clinical factors, behavioral factors, and psycho-social factors. For demographic aspect, factors associated with poor glycemic control include age [8, 10, 11] and sex [8]. For clinical aspect, there are many factors associated with poor glycemic control, including obesity [12, 13], duration of diabetes [7, 8], and diabetes treatment modalities [5, 11]. In the behavioral aspect, factors associated with poor glycemic control include self-care behaviors [12], energy intake [14], physical activities [5, 15, 16], sleeping quality [17], and smoking [7]. In the psycho-social aspect, depression is a common psychological issue associated with poor glycemic control [18]. However, evaluation for depression does not cover the social aspect, which is also important for diabetes treatment outcomes. Therefore, diabetes-related distress (DRD) is one of the important concerns [1921].

DRD refers to a broader affective experience than depression, as it covers both psychological and social aspects. DRD implies worries, concerns, and fears related to the burden of living with diabetes, such as feeling overwhelmed by diabetes management tasks or experiencing negative emotions related to the condition [22]. The prevalence of DRD was 29.4% in Vietnam [23], 37.0% in Saudi Arabia [19], and 39% in Canada [24]. Furthermore, DRD is associated with poor self-management [19, 21] and poor glycemic outcomes [1921]. Despite the importance of DRD in diabetes management, it is often overlooked in clinical settings. Therefore, attending to psycho-social concerns may be the key to achieve the glycemic goal. DRD screening may be an important step in dealing with psycho-social problems in diabetic patients.

While literature has extensively studied demographic, clinical, and behavioral factors affecting glycemic control in patients with type 2 diabetes [5, 7, 8, 1017], there is a knowledge gap concerning psycho-social factors in Thailand. Particularly, the impact of DRD, encompassing both psychological and social aspects, has not been adequately investigated. Therefore, this study aims to investigate: 1) the prevalence and associated factors of poor glycemic control type 2 diabetes, and 2) the prevalence of DRD and the association of its subcomponents and poor glycemic control type 2 diabetes in Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand.

Materials and methods

Study design, setting, and period

A cross-sectional study was conducted from 1st December 2021 to 18th March 2022 at the Outpatient Clinic of the Family Medicine Department, Maharaj Nakorn Chiang Mai Hospital. The hospital is affiliated with the Faculty of Medicine, Chiang Mai University, and functions as both a training center and a tertiary medical care facility for patients in Chiang Mai and 16 other Northern Thai provinces. The outpatient clinic of the Family Medicine department serves as a primary care facility for non-urgent medical conditions. The clinic registers and treats about 9,000 patients each year, with approximately 1,900 cases being type 2 diabetes patients.

Population

The study population consisted of type 2 diabetic patients registered in the family medicine outpatient clinic at our institute. The patients received treatment based on routine guidelines, which include both medication with lifestyle modification and lifestyle modification only. Inclusion criteria were as follows: 1) known cases of type 2 diabetic patients with scheduled appointments and glycated hemoglobin (HbA1c) tests during the study period, 2) aged at least 18 years old, and 3) able to answer the questionnaire and agree to participate in the study. The exclusion criterion was a recent diagnosis of type 2 diabetes within the past 6 months.

Sampling and sample size estimation

Patients were recruited through consecutive sampling. The sample size was calculated using the formula for estimating a proportion in an infinite population [25]. According to relevant literature, we anticipated that about 54.8% of type 2 diabetic patients would have poor glycemic control [9]. We defined a margin of error (d) of 0.10 and a significance level (alpha) of 0.05, with Z(0.975) = 1.96. The calculated sample size was 96 patients. Additionally, an additional 20% was added to account for incomplete responses or missing data.

n=z1α22p(1p)d2

Research instrument and measures

Data, including age, sex, occupation, personal monthly income, education, marital status, health insurance, smoking, alcohol consumption, comorbidities, and duration of being type 2 diabetes, were collected via a questionnaire.

Cognitive screening was performed using the Thai version of the brief cognitive screening test (Mini-Cog) (Cronbach’s α = 0.80) [26, 27], with a score of ≤ 3 indicating cognitive impairment.

Self-care behavior data were assessed using a questionnaire developed by Siangdung et al (Cronbach’s α = 0.70) [28]. This questionnaire consists of 20 questions covering 5 behaviors, including eating, medical adherence, exercise, dealing with stress, and continuing of treatment. Each question is rated on a scale of 1 (not performing), 2 (occasionally performing), and 3 (regularly performing). The mean score for each behavior was categorized into three self-care groups: low (1.00–1.66), medium (1.67–2.33) and high (2.34–3.00).

Physical activity data were collected using the Thai version of the Global Physical Activity Questionnaires (GPAQ) (Cronbach’s α = 0.82) [29, 30], which recorded physical activity data and then calculated the metabolic equivalent (MET). The World Health Organization (WHO) recommends that adequate physical activity includes at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity physical activity per week, or at least 600 MET-minutes per week [30].

Dietary assessment was collected using a 24-hour dietary recall. The research assistant nurse instructed the patients to provide information about the type, name, and amount of food and drink consumed in the previous 24 hours. Total calorie and carbohydrate intake were analyzed by a dietitian, while other data were kept blind to prevent bias.

Sleep quality in the past 1 month was evaluated using the Thai version of the Pittsburgh Sleep Quality Index (PSQI) (Cronbach’s α = 0.84) [31]. This questionnaire consists of 19 questions, with the total score ranging from 0 to 21. A score of ≥5 indicates poor sleep quality.

Depression screening was assessed using 9-Questions Depression Rating Scale (9Q) [32]. This screening tool consists of 9 questions about depressive symptoms experienced within the last 2 weeks. A score of ≥7 indicates a positive result for depression on the 9Q.

DRD was assessed using the Thai version of the Diabetes Distress Scale questionnaire (DDS-17) (Cronbach’s α = 0.95) [33, 34]. This questionnaire consists of 17 questions in 4 different dimensions (emotional distress, regimen-related distress, physician-related distress, and diabetes-related interpersonal distress). Each question is rated on a scale from1 (no problems) to 6 (serious problems). Each dimension was interpreted based on its mean score, resulting in two groups: no distress (< 2) and moderate to high distress (≥ 2).

Moreover, data including weight, height, waist circumference, blood pressure, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), and diabetes treatment modalities were obtained from the electronic medical record. For FBS and HbA1c, whole blood specimens were collected by licensed medical technicians on the same day as the data collection. Patients fasted (nothing per oral, NPO) for 12 hours prior to blood collection. All specimens were properly stored and analyzed by our central laboratory on the same day. The results were then recorded in the electronic medical record. Body mass index (BMI) was calculated by dividing a person’s weight in kilograms by their height in meters squared. In this study, a BMI of ≥ 25 kg/m2 was considered obese [35].

Data collection

Data collection was carried out within a single session at the outpatient clinic. All type 2 diabetic patients who visited the clinic and met the inclusion criteria were voluntarily invited to participate by the outpatient clinic’s nurse. Participants who were willing to participate in the study were directed to a registered nurse who served as a research data collector and was trained to conduct interviews. The registered nurse provided information about the data collection process and obtained written informed consent from the patients.

Subsequently, demographic data were collected through a self-administered paper-based questionnaire, which included information such as age, sex, occupation, personal monthly income, education, marital status, and health insurance. The information that patients had completed was then submitted to the same registered nurse for a thorough check to ensure completeness.

The same registered nurse conducted questionnaire interviews and performed assessments using standard tools, including comorbidities, duration of type 2 diabetes, smoking, alcohol consumption, cognitive screening (Mini-Cog), self-care behaviors (self-care behavior questionnaire), physical activity (GPAQ), dietary assessments (24-hour dietary recall), sleep quality (PSQI), depression screening (9Q), and DRD assessment (DDS-17).

Our registered nurse received training in the use of these questionnaires and assessment tools before starting data collection. In Thailand, registered nurses are qualified to conduct screening tests, such as the self-care behavior questionnaire [28], Mini-Cog [27], GPAQ [29], PSQI [31], 9Q [32], and DDS-17 [33], under the supervision of a family physician. If any abnormalities were detected during the data collection, the assistant nurse would promptly notify the attending family physicians. Otherwise, patients would continue their routine examinations and treatment. In this study, none of the attending family physicians at the outpatient clinic were involved in the data collection process.

Afterward, a research data collection assistant, who was not involved in the collection of questionnaire and patients’ treatment, retrieved data including weight, height, waist circumference, blood pressure, FBS, HbA1c, and diabetes treatment modalities from the electronic medical records of that day. Another research assistant was assigned to double-check the data for completeness, consistency, reliability, and to prevent transcription errors. Subsequently, only dietary assessment data (24-hour dietary recall) were sent to a dietitian for evaluating total calorie and carbohydrate intake, and these were later returned to the main investigator. Only the investigator team had access to information that could identify individual participants during data collection.

Outcome of interest

Glycemic control was determined according to The American Diabetes Association (ADA) Guideline 2021 [36]. The target HbA1c was determined based on age and comorbidities, including: 1) HbA1c < 7.0% (age ≤ 65 years old), 2) HbA1c < 7.5% (age > 65 years old, independent, without cognitive impairment), 3) HbA1c < 8.0% (age > 65 years old with ≥ 3 comorbidities (e.g., hypertension, arthritis, cancer, heart failure, falls, CKD stage ≥ 3, myocardial infarction, stroke), frailty, dementia, dependent). Patients who failed to meet the HbA1c target were classified as having poor glycemic control, whereas those who achieved it were classified as having good glycemic control.

Statistical analysis

The data were analyzed by using Stata 16.0 (StataCorp, College Station, Texas, USA). Descriptive statistics were expressed as frequencies and percentage for categorical data, mean ± SD or median (IQR) for numerical data depending on the underlying distribution. Independent t-test, Mann-Whitney U test and Fisher’s exact test were used to evaluate the significant differences of variables between good and poor glycemic control groups. Factors with statistically significant results from univariable analysis (p-value < 0.05) were further explored using multivariable logistic regression analysis. Additionally, multivariable logistic regression analysis was also used to explore the association between DRD subcomponents and poor glycemic control while adjusting for sex and other factors previously identified as significant in the univariable analysis.

Ethical considerations

Ethical approval was obtained from the Research Ethics Committee, Faculty of Medicine, Chiang Mai University, Thailand (FAM-2564-08500). Written informed consent was obtained from the study participants after they were informed of the study’s purpose.

Results

A total of 160 diabetes patients visited Outpatient Clinic of the Family Medicine Department, Maharaj Nakorn Chiang Mai Hospital during the study period. Among them, 33 patients were excluded: 4 patients were newly diagnosed with type 2 diabetes, and 29 patients did not volunteer to participate in the study. Therefore, 127 patients voluntarily participated in this study.

The mean age was 66.2 ± 7.3 years, ranging from 44 to 83 years old, with female predominance (52%). Most of them were married (73.2%). Median duration of being type 2 diabetes was 8 years (IQR 3,11 years). Among the participants, 88.2% were receiving medical treatment with lifestyle modification, while 11.8% were on lifestyle modification only. Cognitive impairment, as assessed by the Mini-Cog test, was not present in most participants (94.5%). The mean HbA1c was 6.9 ± 0.8% and the prevalence of poor glycemic control type 2 diabetes was 29.1% (31/127). Table 1 presents the comparison of demographic and clinical factors between poor glycemic control and good glycemic control type 2 diabetes. The poor glycemic control group had higher prevalence of age under 65 years old (p-value = 0.014), obesity (p-value = 0.012), using sulfonylurea (p-value = 0.029), and using two or more types of diabetes medication (p-value = 0.012) (Table 1).

Table 1. Comparison of demographic and clinical factors between poor glycemic control and good glycemic control type 2 diabetes (n = 127).

Factor DM treatment outcome p-value
Uncontrolled (n = 37) Controlled (n = 90)
n % n %
Demographic factors
Age
 Age < 65 years old 19 51.4 25 27.8
 Age ≥ 65 years old (elderly) 18 48.6 65 72.2 0.014 c
Sex
 Male 16 43.2 45 50.0
 Female 21 56.8 45 50.0 0.560 c
Occupation
 In employment/working 16 43.2 32 35.6
 Unemployed/not working 21 56.8 58 64.4 0.428 c
Personal monthly income (Thai baht) (median (IQR)) 20000 (10000,32000) 16384 (10000,30000) 0.280 b
Education level
 Lower than bachelor’s degree 20 54.1 50 55.6
 Bachelor’s degree or higher 17 46.0 40 44.4 1.000 c
Marital status
 Married 26 70.3 67 74.4
 Single, separated, divorced, widow 11 29.7 23 25.6 0.663 c
Health Insurance
 Government 36 97.3 85 94.4
 Non-government 1 2.7 5 5.6 0.671 c
Clinical factors
Comorbidities
 > 1 other underlying diseases 30 81.1 81 90.0 0.237 c
Cognitive screening by Mini-Cog
 No cognitive impairment (Mini-Cog > 3) 34 91.9 86 95.6
 Cognitive impairment (Mini-Cog ≤ 3) 3 8.1 4 4.4 0.415 c
Body weight (kg) (mean ± SD) 65.6 ± 11.5 63.5 ± 12.0 0.378 a
Height (cm) (mean ± SD) 157.8 ± 8.3 159.4 ± 8.5 0.329 a
BMI (kg/m2) (mean ± SD) 26.4 ± 4.3 24.9 ± 3.6 0.049 a
 Obesity (BMI ≥ 25 kg/m2) 24 64.9 36 40.0 0.012 c
Waist circumference (cm) (mean ± SD) 88.4 ± 9.5 87.4 ± 10.0 0.621 a
Systolic blood pressure(mmHg) (mean ± SD) 140.5 ± 10.7 136.5 ± 13.1 0.098 a
Diastolic blood pressure(mmHg)(mean ± SD) 79.9 ± 8.8 78.4 ± 9.4 0.422 a
Duration of DM (years) (median (IQR)) 9 (4,10) 8 (3,11) 0.845 b
Diabetes treatment
 Lifestyle modification only 4 10.8 11 12.2
 Medical treatment with lifestyle modification 33 89.2 79 87.8 1.000 c
Type of medication treatment (single or combination regimen)
 Biguanide 32 86.5 76 84.4 1.000 c
 Sulfonylureas 15 40.5 19 21.1 0.029 c
 Thiazolidinedione 2 5.4 3 3.3 0.628 c
 DPP-4 inhibitor 15 40.5 33 36.7 0.692 c
 SGLT-2 inhibitor 2 5.4 2 2.2 0.579 c
 Insulin 0 0 1 1.1 1.000 c
Using ≥ 2 types of DM medication 24 64.9 36 40.0 0.012 c
FBS (mg/dL) (mean ± SD) 155.8 ± 35.0 122.9 ± 16.2 < 0.001a
HbA1c (%) (mean ± SD) 7.8 ±0.6 6.5 ±0.5 <0.001 a

a Independent t-test

b Mann-Whitney U test

c Fisher’s exact test

Concerning behavioral and psycho-social factors, most patients had high level of self-care behavior (84.3%). Regarding medical adherence, a subcomponent of self-care behavior, there were 112 patients receiving medical treatment, and most of them (99.1%) exhibited a high level of medical adherence (110/112). Notably, none of the patients used long-term corticosteroids. Moreover, 22.1% of patients had inadequate physical activity, and 37.7% experienced poor sleep quality. The prevalence of depression and DRD among patients in this study was 6.3% (8/127) and 19.7% (25/127), respectively. Table 2 presents the comparison of behavioral and psycho-social factors between poor glycemic control and good glycemic control type 2 diabetes. In terms of behavioral factors, there were no significant differences in self-care behavior, medical adherence, physical activity, dietary intake, smoking, and alcohol consumption between the two groups. Interestingly, psycho-social factors were particularly remarkable. The poor glycemic control group had higher prevalence of being diabetic patient with distress (p-value<0.001), depression (p-value = 0.046), and poor sleep quality (p-value = 0.008) (Table 2).

Table 2. Comparison of behaviors and psycho-social factors between poor glycemic control and good glycemic control type 2 diabetes (n = 127).

Factor DM treatment outcome p-value
Uncontrolled (n = 37) Controlled (n = 90)
n % n %
Behavioral factors
Current smoking 4 10.8 2 2.2 0.059 c
Current alcohol drinking 13 35.1 20 22.2 0.181 c
Frequency of alcohol drinking (n = 33)
 ≤ 1 time per month 7 53.8 8 40.0
 2–4 times per month 2 15.4 4 20.0
 >2 times per week 4 30.8 8 40.0 0.810 c
Amount of alcohol consumed (Standard drinks per time) (median (IQR)) 3.2 (1.28,5) 2 (1,4.5) 0.401 b
 Self-care behavior (Total Health Behavior score) (mean ± SD) 2.5 ± 0.2 2.6 ± 0.2 0.221 a
 High (score 2.34–3.00) 31 83.8 76 84.4
 Medium (score 1.67–2.33) 6 16.2 14 15.6
 Low (score 1.00–1.66) 0 0 0 0 1.000 c
Medical adherence score (n = 112) (mean ± SD) 2.6 ± 0.2 2.7 ± 0.2 0.152 a
 High (score 2.34–3.00) 32 97.0 78 98.7
 Medium (score 1.67–2.33) 1 3.0 1 1.3
 Low (score 1.00–1.66) 0 0 0 0 0.504 c
Physical activity (MET score) (median (IQR)) 880 (560,2860) 1120 (720,2120) 0.538 b
 Inadequate physical activity 11 29.7 17 18.9 0.238 c
24 hr. Dietary Recall
 Carbohydrate (kcal/day) (mean ± SD) 829.9 ±347.4 851.9 ±332.7 0.738 a
 Total calory (kcal/day) (mean ± SD) 1598.6 ±463.9 1657.3 ±510.0 0.546 a
Sleep quality by PSQI score
 Poor sleep quality (PSQI >5) 21 56.8 27 30.0 0.008 c
Psycho-social factors
Screening Depression by 9Q
 Positive (9Q ≥ 7) 5 13.5 3 3.3 0.046 c
DRD by DDS-17 score
 No distress (score <2) 18 48.7 84 93.3
 With distress (score ≥ 2) 19 51.4 6 6.7 < 0.001 c

a Independent t-test

b Mann-Whitney U test

c Fisher’s exact test

Table 3 presents multivariable logistic regression analysis of association between poor glycemic control type 2 diabetes and potential related factors. Factors significantly associated with poor glycemic control type 2 diabetes were age under 65 years old (p-value = 0.001), obesity (p-value = 0.041), and being diabetic patient with distress (p-value<0.001) (Table 3).

Table 3. Multivariable logistic regression analysis of association between poor glycemic control type 2 diabetes and potential related factors (n = 127).

Factor Odd Ratio 95% CI p-value
Age
 Age ≥ 65 years old (elderly) Reference
 Age < 65 years old 6.40 2.07–19.77 0.001
Sex
 Male Reference
 Female 1.66 0.58–4.77 0.343
BMI
 Not obesity (BMI < 25) Reference
 Obesity (BMI ≥ 25) 2.96 1.05–8.39 0.041
Using sulfonylureas
 Not using sulfonylureas Reference
 Using sulfonylureas 1.91 0.52–7.09 0.331
Diabetes medication
 Lifestyle modification or using 1 type of DM medication Reference
 Using two or more types of diabetes medication 1.89 0.55–6.47 0.313
DRD by DDS-17 score
 No distress (score < 2) Reference
 With distress (score ≥ 2) 14.20 3.76–53.64 <0.001
Screening depression (9Q)
 No depression (9Q < 7) Reference
 Depression (9Q ≥ 7) 2.88 0.31–26.33 0.349
Sleep quality by PSQI score
 Normal sleep quality (PSQI ≤ 5) Reference
 Poor sleep quality (PSQI > 5) 2.01 0.66–6.14 0.219

Table 4 presents the comparison of DDS-17 dimensions between poor glycemic control and good glycemic control type 2 diabetes. The prevalence of emotional distress was 26.0%, regimen-related distress was 22.1%, physician-related distress was 3.2%, and diabetes-related interpersonal distress was 12.6%. Moreover, the group with poor glycemic control had higher prevalence of emotional distress (p-value<0.001), regimen-related distress (p-value<0.001) and diabetes-related interpersonal distress (p-value = 0.001) (Table 4).

Table 4. Comparison of DDS-17 dimensions between poor glycemic control and good glycemic control type 2 diabetes (n = 127).

Factor DM treatment outcome p-value
Uncontrolled (n = 37) Controlled (n = 90)
n % n %
 Emotional distress
 No distress (score <2) 18 48.7 76 84.4
 With distress (score ≥ 2) 19 51.3 14 15.6 <0.001 c
Regimen-related distress
 No distress (score <2) 19 51.3 80 88.9
 With distress (score ≥ 2) 18 48.7 10 11.1 <0.001 c
Physician-related distress
 No distress (score <2) 35 94.6 88 97.8
 With distress (score ≥ 2) 2 5.4 2 2.2 0.579 c
Diabetes-related interpersonal distress
 No distress (score <2) 26 70.3 85 94.4
 With distress (score ≥ 2) 11 29.7 5 5.6 0.001 c

c Fisher’s exact test

Table 5 presented multivariable logistic regression analysis of association between poor glycemic control type 2 diabetes and DDS-17 dimensions. Emotional distress (p-value = 0.006), regimen-related distress (p-value = 0.003), and diabetes-related interpersonal distress (p-value = 0.015) were associated with uncontrolled type 2 diabetes after adjusted for age, sex, obesity, using sulfonylureas, using two or more types of diabetes medication, depression, and poor sleep quality (Table 5).

Table 5. Multivariable logistic regression analysis of association between poor glycemic control type 2 diabetes and DDS-17 dimensions (n = 127).

Factor Odd Ratio 95% CI p-value
Emotional distress
 No distress (score <2) Reference
 With distress (score ≥ 2) 4.23 1.51–11.85 0.006
Regimen-related distress
 No distress (score <2) Reference
 With distress (score ≥ 2) 6.00 1.88–19.18 0.003
Physician-related distress
 No distress (score <2) Reference
 With distress (score ≥ 2) 1.22 0.11–13.23 0.869
Diabetes-related interpersonal distress
 No distress (score <2) Reference
 With distress (score ≥ 2) 5.25 1.38–20.02 0.015

Adjust for age, sex, obesity, using sulfonylureas, using two or more types of diabetes medication, depression, and poor sleep quality.

Discussion

The purpose of this study was to investigate the prevalence of poor glycemic control in patients with type 2 diabetes and its association with clinical factors and diabetes-related distress in a primary care setting. The prevalence of poorly controlled type 2 diabetes in our study was 29.1%, which was lower than in previous studies: 47.3% in Brazil [5], 50.2% in Japan [6], and 84.3% in Uganda [10]. The difference in prevalence might be attributed to variations in HbA1c target goals. Some countries adopt an HbA1c goal of less than 7% [6, 10], while others follow the HbA1c goal outlined in the ADA guideline for 2021 [5], which allows for greater flexibility, especially for older patients. The sociodemographic characteristics of patients and the university affiliation may have influenced the lower prevalence of poor glycemic control [5].

From our analysis, we have identified three factors independently associated with poor glycemic control. The first factor was being under 65 years old, which was consistent with findings from previous studies [811]. This association can be explained by the fact that younger to middle-aged patients may be more occupied with work and more likely to miss doctor’s appointments and disregard self-care behaviors, resulting in poor glycemic control [810]. Conversely, elderly patients might be more motivated to manage their diabetic conditions [8]. Additionally, this may be due to the flexible HbA1c target range for the elderly in the ADA guideline for 2021 [36]. The second factor, obesity was also supported by previous studies [12, 13] that patients with greater BMI, who were expected to have low physical activity levels, were more likely to experience poor glycemic control compared to those with a normal BMI [12]. Furthermore, evidence supports the hypothesis that obesity was associated with insulin resistance and beta-cell dysfunction, leading to hyperglycemia [37]. Therefore, addressing obesity through weight reduction interventions could potentially improve glycemic control and overall health status in individuals with poorly controlled type 2 diabetes [38].

The last factor was DRD. The prevalence of diabetic patients with DRD in this study was 19.7%, which closely aligns with figures reported in previous studies, such as 22.6% in Greece [39], 25% in Saudi Arabia [40], and 29.4% in Vietnam [23]. However, another study conducted in Canada showed a higher prevalence of DRD, at 39% [24]. This result indicates that the prevalence of DRD varies among different countries and service settings. The association of DRD with poor glycemic control was in conformity with the results of previous studies conducted in Japan [20], Saudi Arabia [19], and the United States [41]. Previous studies have found that DRD, as opposed to depression, was associated with higher HbA1c levels [20, 21]. DRD was also associated with a low level of autonomy support [41], poor treatment adherence [19], and poor glycemic control [19, 41]. Furthermore, there is evidence supporting the idea that DRD could lead to dysregulation of stress hormones and subsequent hyperglycemia [39].

Regarding the subcomponents analysis of DRD, it was found that emotional distress and regimen-related distress were common among type 2 diabetic patients in this study. The prevalence of emotional distress was 26.0%, regimen-related distress was 22.1%, physician-related distress was 3.2%, and diabetes-related interpersonal distress was 12.6%. Our analysis found a significant association between emotional distress, regimen-related distress, and diabetes-related interpersonal distress with poor glycemic control type 2 diabetes, which was consistent with previous studies [24, 39, 42]. Studies have found an association between emotional distress and poor glycemic control, which could be attributed to the psychological stress of managing their condition [24, 39, 42]. Furthermore, diabetes-related interpersonal distress has also been found to be associated with poor glycemic control [39], possibly due to the challenges of maintaining social relationships while coping with the impact of diabetes on daily life. Additionally, regimen-related distress has been linked to poor medication adherence [43] and higher HbA1c levels [24, 39], which may be related to difficulties in adhering to medication and self-care management. Moreover, evidence supports that a lower level of DRD score is positively associated with better glycemic control [23]. Therefore, the DDS-17 could be used to assess patients’ specific concerns and assist in personalized diabetes management plans. Additionally, studies have revealed that interventions such as peer support and brief group cognitive-behavioral therapy can effectively reduce DRD and improve glycemic control in poorly controlled type 2 diabetic patients with DRD [44, 45]. Consequently, appropriate DRD detection and management through screening and the implementation of interventions, such as cognitive-behavioral therapy or supervision, could enhance self-care and improve treatment outcomes for diabetic patients.

In addition to the factors previously discussed, previous studies have also identified other factors associated with poor glycemic control, such as medical adherence [46], depression [18], and poor sleep quality [17]. However, these findings were inconsistent with the results of our study. The high adherence among most of the included patients may have limited the significance of medical adherence in our study. Additionally, depression and sleep quality showed only potential but not significant associations with poor glycemic control, possibly due to the small sample size. Studies with larger sample sizes could provide more robust findings.

The main strength of the study is the comprehensive evaluation of potential factors associated with poor glycemic control in type 2 diabetes across multiple dimensions, including demographic, clinical, behavioral, and psychosocial factors. This approach provides a more holistic view of the factors associated with poor glycemic control. Another strength of the study is the use of standardized tools for data collection and analysis, which enhanced the accuracy and reliability of the results. The expertise of a dietitian also improved the quality of the results, particularly in dietary assessment. Moreover, the utilization of two trained assistants to collect data separately in their assigned areas minimized inconsistencies in data collection. However, this study has some limitations. Firstly, its cross-sectional design does not allow for the confirmation of a causal relationship between factors potentially associated with poor glycemic control in type 2 diabetes. A cohort design, which follows a population at risk over time, may be better suited for causal inference. Secondly, there may have been some recall bias due to the high proportion of elderly patients. However, this bias is likely minimal because most of the patients had no cognitive impairment. Thirdly, as we did not perform an official sample size estimation for conducting the multivariable analysis, some important factors might not have reached statistical significance. The interpretation of our results should focus on the direction and effect size rather than solely on statistical significance, and further research with a larger study size is encouraged to explore relevant factors and validate our findings more comprehensively. Finally, the study population was limited to patients at our family medicine clinic. This limitation may impact the generalizability of the findings. To enhance the generalizability of the results, future studies should include a more diverse population.

Conclusion

In conclusion, although the prevalence of poor glycemic control in type 2 diabetes was relatively low in this study, it remains a significant issue deserving attention. We identified factors linked to poor glycemic control, including age under 65, obesity, and DRD. Additionally, three dimensions of DRD (emotional distress, regimen-related distress, and diabetes-related interpersonal distress) were associated with poor glycemic control. These findings emphasize the need for a holistic approach to diabetes management, encompassing demographic, clinical, behavioral, and psychosocial factors in patient care.

Supporting information

S1 File. Study flow.

(DOCX)

Acknowledgments

The authors thank the Family Medicine Department, Maharaj Nakorn Chiang Mai Hospital for their support, the OPD family medicine staff for their help in patient recruitment, and all participants for providing informative data and giving permission for its publication.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This study was supported by Faculty of Medicine, Chiang Mai University grant number 035/2566. https://w1.med.cmu.ac.th/research/Homepage/Default.html#. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes—Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–11. doi: 10.2991/jegh.k.191028.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.International Diabetes Federation. IDF Diabetes Atlas 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. p. 5–6. [Google Scholar]
  • 3.Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2020;10(4):174–88. doi: 10.4103/ajm.ajm_53_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Reutrakul S, Deerochanawong C. Diabetes in Thailand: Status and Policy. Current Diabetes Reports. 2016;16(3):28. doi: 10.1007/s11892-016-0725-7 [DOI] [PubMed] [Google Scholar]
  • 5.Espinosa MM, Almeida V, Nascimento VFD. Poor glycemic control and associated factors in diabetic people attending a reference outpatient clinic in Mato Grosso, Brazil. Invest Educ Enferm. 2021;39(3). doi: 10.17533/udea.iee.v39n3e10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gouda M, Matsukawa M, Iijima H. Associations between eating habits and glycemic control and obesity in Japanese workers with type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2018;11:647–58. doi: 10.2147/DMSO.S176749 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Riaz F, Al Shaikh A, Anjum Q, Mudawi Alqahtani Y, Shahid S. Factors related to the uncontrolled fasting blood sugar among type 2 diabetic patients attending primary health care center, Abha city, Saudi Arabia. Int J Clin Pract. 2021;75(7):e14168. doi: 10.1111/ijcp.14168 [DOI] [PubMed] [Google Scholar]
  • 8.Sakboonyarat B, Pima W, Chokbumrungsuk C, Pimpak T, Khunsri S, Ukritchon S, et al. National trends in the prevalence of glycemic control among patients with type 2 diabetes receiving continuous care in Thailand from 2011 to 2018. Scientific Reports. 2021;11(1):14260. doi: 10.1038/s41598-021-93733-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Yeemard F, Srichan P, Apidechkul T, Luerueang N, Tamornpark R, Utsaha S. Prevalence and predictors of suboptimal glycemic control among patients with type 2 diabetes mellitus in northern Thailand: A hospital-based cross-sectional control study. PLoS One. 2022;17(1):e0262714. doi: 10.1371/journal.pone.0262714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Patrick NB, Yadesa TM, Muhindo R, Lutoti S. Poor Glycemic Control and the Contributing Factors Among Type 2 Diabetes Mellitus Patients Attending Outpatient Diabetes Clinic at Mbarara Regional Referral Hospital, Uganda. Diabetes Metab Syndr Obes. 2021;14:3123–30. doi: 10.2147/DMSO.S321310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Marczynski M, Cortellazzi K, Barberato-Filho S, Motta R, Vieira A, Quilici M, et al. Unsatisfactory glycemic control in type 2 Diabetes mellitus patients: predictive factors and negative clinical outcomes with the use of antidiabetic drugs. Brazilian Journal of Pharmaceutical Sciences. 2016;52:801–12. [Google Scholar]
  • 12.Almomani MH, Al-Tawalbeh S. Glycemic Control and Its Relationship with Diabetes Self-Care Behaviors Among Patients with Type 2 Diabetes in Northern Jordan: A Cross-Sectional Study. Patient Prefer Adherence. 2022;16:449–65. doi: 10.2147/PPA.S343214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Boye KS, Lage MJ, Thieu V, Shinde S, Dhamija S, Bae JP. Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data. J Diabetes Complications. 2021;35(9):107975. doi: 10.1016/j.jdiacomp.2021.107975 [DOI] [PubMed] [Google Scholar]
  • 14.Kang HM, Kim DJ. Total energy intake may be more associated with glycemic control compared to each proportion of macronutrients in the korean diabetic population. Diabetes Metab J. 2012;36(4):300–6. doi: 10.4093/dmj.2012.36.4.300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Park JH PhD, Lee YE PhD. Effects of exercise on glycemic control in type 2 diabetes mellitus in Koreans: the fifth Korea National Health and Nutrition Examination Survey (KNHANES V). J Phys Ther Sci. 2015;27(11):3559–64. doi: 10.1589/jpts.27.3559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ahn J, Yang Y. Factors Associated with Poor Glycemic Control Amongst Rural Residents with Diabetes in Korea. Healthcare (Basel). 2021;9(4). doi: 10.3390/healthcare9040391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tang Y, Meng L, Li D, Yang M, Zhu Y, Li C, et al. Interaction of sleep quality and sleep duration on glycemic control in patients with type 2 diabetes mellitus. Chin Med J (Engl). 2014;127(20):3543–7. [PubMed] [Google Scholar]
  • 18.Papelbaum M, Moreira RO, Coutinho W, Kupfer R, Zagury L, Freitas S, et al. Depression, glycemic control and type 2 diabetes. Diabetol Metab Syndr. 2011;3(1):26. doi: 10.1186/1758-5996-3-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Fayed A, AlRadini F, Alzuhairi RM, Aljuhani AE, Alrashid HR, Alwazae MM, et al. Relation between diabetes related distress and glycemic control: The mediating effect of adherence to treatment. Prim Care Diabetes. 2022;16(2):293–300. doi: 10.1016/j.pcd.2021.12.004 [DOI] [PubMed] [Google Scholar]
  • 20.Tsujii S, Hayashino Y, Ishii H. Diabetes distress, but not depressive symptoms, is associated with glycaemic control among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 1). Diabet Med. 2012;29(11):1451–5. doi: 10.1111/j.1464-5491.2012.03647.x [DOI] [PubMed] [Google Scholar]
  • 21.Fisher L, Glasgow RE, Strycker LA. The relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes. Diabetes Care. 2010;33(5):1034–6. doi: 10.2337/dc09-2175 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabet Med. 2014;31(7):764–72. doi: 10.1111/dme.12428 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Huynh G, Tran TT, Do THT, Truong TTD, Ong PT, Nguyen TNH, et al. Diabetes-Related Distress Among People with Type 2 Diabetes in Ho Chi Minh City, Vietnam: Prevalence and Associated Factors. Diabetes Metab Syndr Obes. 2021;14:683–90. doi: 10.2147/DMSO.S297315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wong EM, Afshar R, Qian H, Zhang M, Elliott TG, Tang TS. Diabetes Distress, Depression and Glycemic Control in a Canadian-Based Specialty Care Setting. Can J Diabetes. 2017;41(4):362–5. doi: 10.1016/j.jcjd.2016.11.006 [DOI] [PubMed] [Google Scholar]
  • 25.Daniel WW. Biostatistics: A foundation of analysis in the health sciences. John Wiley&Sons. 1995:180. [Google Scholar]
  • 26.Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451–4. doi: 10.1046/j.1532-5415.2003.51465.x [DOI] [PubMed] [Google Scholar]
  • 27.Trongsakul S, Lambert R, Clark A, Wongpakaran N, Cross J. Development of the Thai version of Mini-Cog, a brief cognitive screening test. Geriatrics & Gerontology International. 2015;15(5):594–600. doi: 10.1111/ggi.12318 [DOI] [PubMed] [Google Scholar]
  • 28.Siangdung S. Self-Care Behaviors of Patients with Uncontrolled DM. The Southern College Network Journal of Nursing and Public Health. 2017;4(1):191–204. [Google Scholar]
  • 29.Jaturapatporn D, Hathirat S, Manataweewat B, Dellow AC, Leelaharattanarak S, Sirimothya S, et al. Reliability and validity of a Thai version of the General Practice Assessment Questionnaire (GPAQ). J Med Assoc Thai. 2006;89(9):1491–6. [PubMed] [Google Scholar]
  • 30.World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide Switzerland: World Health Organization; [updated 2019 February; cited 2022 Apirl]. Available from: https://www.who.int/docs/default-source/ncds/ncd-surveillance/gpaq-analysis-guide.pdf?sfvrsn=1e83d571_2. [Google Scholar]
  • 31.Sitasuwan T, Bussaratid S, Ruttanaumpawan P, Chotinaiwattarakul W. Reliability and validity of the Thai version of the Pittsburgh Sleep Quality Index. J Med Assoc Thai. 2014;97 Suppl 3:S57–67. [PubMed] [Google Scholar]
  • 32.Kongsuk T, Arunpongpaisal S, Janthong S, Prukkanone B, Sukhawaha S, Leejongpermpoon J. Criterion-Related Validity of the 9 Questions Depression Rating Scale revised for Thai Central Dialect. J psychiatr Assoc Thaolanf. 2018;63(4):321–44. [Google Scholar]
  • 33.Thanakwang K, Thinganjana W, Konggumnerd R. Psychometric properties of the Thai version of the Diabetes Distress Scale in diabetic seniors. Clin Interv Aging. 2014;9:1353–61. doi: 10.2147/CIA.S67200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–31. doi: 10.2337/diacare.28.3.626 [DOI] [PubMed] [Google Scholar]
  • 35.Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1–203. [DOI] [PubMed] [Google Scholar]
  • 36.American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S168–S79. [DOI] [PubMed] [Google Scholar]
  • 37.Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587–91. doi: 10.2147/DMSO.S67400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, et al. Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies—EASO Can Lead the Way. Obes Facts. 2017;10(5):483–92. doi: 10.1159/000480525 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kintzoglanakis K, Gkousiou A, Vonta P, Sagmatopoulos A, Copanitsanou P. Depression, anxiety, and diabetes-related distress in type 2 diabetes in primary care in Greece: Different roles for glycemic control and self-care. SAGE Open Medicine. 2022;10:20503121221096605. doi: 10.1177/20503121221096605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Aljuaid MO, Almutairi AM, Assiri MA, Almalki DM, Alswat K. Diabetes-Related Distress Assessment among Type 2 Diabetes Patients. J Diabetes Res. 2018;2018:7328128. doi: 10.1155/2018/7328128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Lee AA, Piette JD, Heisler M, Rosland AM. Diabetes Distress and Glycemic Control: The Buffering Effect of Autonomy Support From Important Family Members and Friends. Diabetes Care. 2018;41(6):1157–63. doi: 10.2337/dc17-2396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ogbera A, Adeyemi-Doro A. Emotional distress is associated with poor self care in type 2 diabetes mellitus. J Diabetes. 2011;3(4):348–52. doi: 10.1111/j.1753-0407.2011.00156.x [DOI] [PubMed] [Google Scholar]
  • 43.Cummings DM, Lutes L, Littlewood K, DiNatale E, Hambidge B, Schulman K, et al. Regimen-Related Distress, Medication Adherence, and Glycemic Control in Rural African American Women With Type 2 Diabetes Mellitus. Ann Pharmacother. 2014;48(8):970–7. doi: 10.1177/1060028014536532 [DOI] [PubMed] [Google Scholar]
  • 44.Mizokami-Stout K, Choi H, Richardson CR, Piatt G, Heisler M. Diabetes Distress and Glycemic Control in Type 2 Diabetes: Mediator and Moderator Analysis of a Peer Support Intervention. JMIR Diabetes. 2021;6(1):e21400. doi: 10.2196/21400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Tunsuchart K, Lerttrakarnnon P, Srithanaviboonchai K, Likhitsathian S, Skulphan S. Benefits of Brief Group Cognitive Behavioral Therapy in Reducing Diabetes-Related Distress and HbA1c in Uncontrolled Type 2 Diabetes Mellitus Patients in Thailand. Int J Environ Res Public Health. 2020;17(15). doi: 10.3390/ijerph17155564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Sendekie AK, Netere AK, Kasahun AE, Belachew EA. Medication adherence and its impact on glycemic control in type 2 diabetes mellitus patients with comorbidity: A multicenter cross-sectional study in Northwest Ethiopia. PLOS ONE. 2022;17(9):e0274971. doi: 10.1371/journal.pone.0274971 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Shairyzah Ahmad Hisham

18 Jun 2023

PONE-D-23-07649Physical, behavioral, and psychosocial factors associated with uncontrolled type 2 diabetes: a Northern Thai cross-sectional study.PLOS ONE

Dear Dr. yingchankul,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please note the comments made by the 2 reviewers below and in the attached file and make the necessary amendments. 

Please submit your revised manuscript by Aug 02 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Shairyzah Ahmad Hisham, PhD.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2.Thank you for stating the following in your Competing Interests section: 

“The authors declare no conflict of interest.”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state ""The authors have declared that no competing interests exist."", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Reviewer #1: Dear author,

Although I think this is a good study that could offer new information and potentially improve diabetic care among patients, there were a few major parts of the manuscript that require revision.

Please kindly refer to the attached document. The document is the submitted manuscript containing track changes and suggestions.

Reviewer #2: Dear authors, congratulations on completing the research and producing an illustrative manuscript!

My comments only serve to improve the clarity of reading and transparency of scientific reporting.

Title

The use of the word “Physical factor” in this manuscript may be misleading and not according to usual diabetes mellitus literature. Please consider using conventional terminology.

Abstract

Aside from “lack of studies,” please justify the need to study DRD in Thai diabetic population using other reasons.

Please use the signpost method: A→B, B→C, C→D, in order to write a cohesive background. At present, the background consists of 3 disjointed/non-cohesive sentences.

Please re-consider the usage of the words “physical data” and use “sociodemographic, clinical, etc. data” instead. “Diabetic information” can be rephrased as “disease-related information” or simply “clinical data”.

Please re-write the conclusion with better English sentence structure.

Introduction

Line 66 – Please improve sentence to “is of importance” or “is important”

Line 73 – Please justify the use of “physical factors” to denote age, sex, BMI, duration of diabetes and treatment modalities. None of the cited references that were included in the reference list had used the term “physical factors.” Physical factors usually denote physical activity or physical environment. Please go through the literature and use conventional definitions such as demographics, socioeconomics, sociodemographic, clinical, lifestyle-related, disease-related etc..

Line 81 – Please consider removing the word “trending”. Two out of the 3 citations ranged from earlier publications i.e. year 2010 and year 2012, implicating that diabetes-related distress is not a new concern.

Line 82 – The introduction is DRD heavy, with a whole dedicated paragraph to it. It is also one of the objectives and makes up one-third of the results, with its own logistic regression table. It deserves an emphasis whether in the title or in the objective.

Line 97 – Please separate between the prevalence of uncontrolled type-2 diabetes mellitus and prevalence of risk factors for uncontrolled type-2 diabetes mellitus. At present, the objectives are not stated clearly enough.

Line 93 & 94 – Please support your sentence with several citations.

Materials and methods

Line 113 – Please state whether all type 2 diabetic patients are recruited, regardless whether they are receiving pharmacological management or not.

Line 115 – Please clarify the definition of newly diagnosed i.e., 1 month? 1 year? etc. Please omit automatic exclusions such as “unwillingness to answer…” because your inclusion criteria require “willingness to answer.”

Line 119 – Please justify the choice of this sample size formula. Please clarify whether the amount of diabetic outpatients were considered infinite or finite population. Please confirm whether the final sample size was sufficient for running a regression analysis.

Line 120 – Please state (cite) where the reference value of “50.2%” was obtained from and whether it was specific to Thailand/Northern Thailand. If not, please justify the selection of that particular value.

Line 124 – Please state in details whether the complete data collection process was conducted in one session or multiple small sessions. Please state who conducted the data collection, how long did it take, where did it take place. Was each section an individual interview or a patient self-reported questionnaire?

Line 127 – For data extracted from medical records, please state which values were taken. Was data extracted on the same day as patient interview? Was data from upon diagnosis, or the latest value or otherwise? Please state whether extraction was done uniformly across study population. Was the person who the extracted data from medical records also the same person who conducted the interview? Was there any counterchecking to prevent errors in transcribing?

Line 128 – As HbA1c is the most important outcome data in this study, describe in detail how HbA1c level is measured and recorded into the medical file (manual? electronic?)

Line 153 – Depression is a medical diagnosis. Please state whether depression is physician-diagnosed depression or based on obtaining a score in a questionnaire. Was the questionnaire administrator for 9Q trained or qualified to conduct the questionnaire (i.e. must is be a doctor with training in psychiatry)?

Line 187 – Please also state the age range, to better describe the population demographics.

Line 189 – Please state the formula for calculation of prevalence values (uncontrolled DM / DRD/ etc.) in your study.

Table 1 & Table 2

- For occupation, please change “Job / No job” to “In employment/Working/Unemployed/Not working” etc.

- For education level, was the p-value reported twice?

- Please clarify whether Married, living with family is the same as Married (as opposed to Single/not married)

- For diabetes treatment, explain how p-value was derived. Is it a crosstabulation of all treatment or by each treatment type? Please justify whether crosstabulation by each treatment type is appropriate.

- Please denote tests used for deriving p-values. Please confirm the test used for analysing income, duration of DM and physical activity.

Line 215 and 235 – Please consider reporting the regression model significance and fit.

Line 239 – Please state how adjustment was carried out

Discussion

- Please limit stating the results multiple times as they were already stated in the results section in paragraph and also in the tables.

- The discussion was written in a particular format: “The following factors (x,y,z) was associated with uncontrolled type 2 diabetes mellitus, this was consistent with other studies (A,B,C…)”. Although not incorrect, however, the discussion can be improved by using different variations of the format.

- Results were referenced with other supporting studies. However, were there any inconsistent results or opposing studies? Please elaborate on why your results were unique to your community.

- Please discuss the effect of confounders on the results of your study. For example, medication adherence plays an important role in the control of glucose levels, was medication adherence assessed? Similarly, were medication doses optimised and were the patients treated with appropriate medications according to the guidelines i.e. monotherapy, combination OAD, intensive insulin. If these issues are not addressed or controlled for – it can be said that that failure to achieve HbA1c targets may also come from medication under-optimisation and medication non-compliance. How about being on concurrent medications that increases blood sugar levels such as long-term corticosteroids?

Conclusions

- Conclusions were well-written.

General comments

Although English was overall of good level, typos and grammar improvements are needed here and there. Professional proofreading is recommended to elevate manuscript quality.

Majority of the references are recent publications (publish within 10 years).

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-23-07649_reviewer comments.pdf

PLoS One. 2023 Nov 27;18(11):e0294810. doi: 10.1371/journal.pone.0294810.r002

Author response to Decision Letter 0


27 Jul 2023

To reviewer 1: Thank you for the opportunity. We have incorporated all reviewers' suggestions into the manuscript revision. Moreover, we have added separate file responses to reviewers 1 and 2.

To reviewer 2: Thank you for the opportunity. We have incorporated all reviewers' suggestions into the manuscript revision. Moreover, we have added separate file responses to reviewers 1 and 2.

Attachment

Submitted filename: response to reviewer2.docx

Decision Letter 1

Shairyzah Ahmad Hisham

21 Aug 2023

PONE-D-23-07649R1Prevalence and associated factors of poor glycemic control type 2 diabetes: a Northern Thai cross-sectional study.PLOS ONE

Dear Dr. yingchankul,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but further minor revision will help to produce a manuscript of better clarity and standard. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please refer to the reviewers' comments at the end of this email.

Please submit your revised manuscript by Oct 05 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Shairyzah Ahmad Hisham, PhD.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: Partly

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Reviewer #1: Dear authors,

Thank you for considering all suggestions made in my first reviewed version of the manuscript. I would like to add a few minor suggestions for further improvement of the manuscript. Please refer to below:

1. HbA1C - to change case for 'C' --> HbA1c

2. Acronyms - to introduce the acronyms e.g., DRD, ADA etc. once in the manuscript.

Other than that, the R1 version is a more easy-read version and it highlights the amount of work done by the researchers.

Thank you and all the best.

Reviewer #2: Congratulations on the submission of the reviewed manuscript. Thank you for making the required corrections. My comments serve to improve the clarity of reading and transparency of scientific reporting.

Title: Consider adding DRD in the title to reflect the large portion of research and discussion on DRD in the study and manuscript.

Introduction: Sufficiently written to provide background for justification of research

Objectives: Clear

Method:

Line 121: Please change typo in “Estimating and infinite population…” to “Estimating an infinite population…”

Instrument and data collection:

This subsection requires re-writing for clarity and transparency. My concerns are 1) English language, grammar and writing and 2) details – There were various data collection and scales being used. Was/were the data collector(s) trained and eligible to use the various tools/scales? Or was specifically-trained person required i.e. medical doctor etc.?

Line 129 – line 131: Please consider combining into 1 sentence and state who (research assistant) and how data was collected (extraction from database etc.)

Line 132 – State who did the cognitive screening (state the qualification, doctor? Nurse? Bachelor or graduate student?) and whether that person is eligible to do the screening.

Line 139 – Is this “questionnaire” a patient-reported questionnaire or an interviewer-guided questionnaire? Please state in manuscript. Please state whether the person who the extracted data from medical records also the same person who conducted the interview? Was there any counterchecking to prevent errors in transcribing?

Line 157 –Was the questionnaire administrator for 9Q trained or qualified to conduct the questionnaire (i.e. must be a doctor with training in psychiatry)?

Line 186 – As HbA1c is the most important outcome data in this study, describe in detail how HbA1c level is measured (etc. whole blood? Fasting state? Point of care?)

Results:

Table 1 & 2: Please clarify the use of Fisher’s exact test for the comparison of median values between groups.

Table 3 & 5 – Please consider reporting the regression model significance and fit.

Discussion

Line 322 – Please check and correct the unit; whether mg/dL or mmol/L.

Professional proofreading is recommended to elevate writing quality of discussion section.

Conclusions

Conclusions were well-written.

General comments

Majority of the references are recent publications (published within 10 years).

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 27;18(11):e0294810. doi: 10.1371/journal.pone.0294810.r004

Author response to Decision Letter 1


2 Oct 2023

Reviewer1: I have incorporated all of your suggestions into my revision. They were very helpful. Thank you.

Reviewer2: I have incorporated all of your suggestions into my revision. They were very helpful. Thank you.

Attachment

Submitted filename: response to reviewer2.docx

Decision Letter 2

Shairyzah Ahmad Hisham

10 Nov 2023

Prevalence and the Association between Clinical Factors and Diabetes-Related Distress (DRD) with Poor Glycemic Control in Patients with Type 2 Diabetes: A Northern Thai Cross-Sectional Study

PONE-D-23-07649R2

Dear Dr. yingchankul,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Shairyzah Ahmad Hisham, PhD.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

After 2 revisions, the manuscript is now accepted for publication. However, it is strongly recommended to send the manuscript for proofreading to ensure that all grammatical and formatting errors are addressed prior to publication. Congratulation!

Acceptance letter

Shairyzah Ahmad Hisham

14 Nov 2023

PONE-D-23-07649R2

Prevalence and the Association between Clinical Factors and Diabetes-Related Distress (DRD) with Poor Glycemic Control in Patients with Type 2 Diabetes: A Northern Thai Cross-Sectional Study

Dear Dr. Yingchankul:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Shairyzah Ahmad Hisham

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Study flow.

    (DOCX)

    Attachment

    Submitted filename: PONE-D-23-07649_reviewer comments.pdf

    Attachment

    Submitted filename: response to reviewer2.docx

    Attachment

    Submitted filename: response to reviewer2.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES